Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice

Molecular and Cellular Biochemistry

Volumn 379, Issue 1-2, 2013, Pages 97-105

  Mourouzis, Iordanis ^a   Kostakou, Erietta ^a   Galanopoulos, Georgios ^a   Mantzouratou, Polixeni ^a   Pantos, Constantinos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Heart failure; Kinase signaling; Myocardial infarction; Thyroid hormone; TR 1 receptor

Indexed keywords

DRONEDARONE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN BETA; PHOSPHOLAMBAN; THYROID HORMONE RECEPTOR ALPHA;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART RATE; HEART SIZE; INOTROPISM; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WALL STRESS;

AMIODARONE; ANIMALS; CALCIUM-BINDING PROTEINS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOSINS; ORGAN SIZE; PROTEIN ISOFORMS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; STROKE VOLUME; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONES; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; MUS;

EID: 84878442858     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1631-9     Document Type: Article

References (36)

1. De Groot LJ (1999) Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84:151-164
2. Friberg L, Werner S, Eggertsen G, Ahnve S (2002) Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 162:1388-1394
3. Lazzeri C, Sori A, Picariello C, Chiostri M, Gensini GF, Valente S (2012) Nonthyroidal illness syndrome in ST-elevation myocardial infarction treated with mechanical revascularization. Int J Cardiol 158:103-104
4. Lymvaios I, Mourouzis I, Cokkinos DV, Dimopoulos MA, Toumanidis ST, Pantos C (2011) Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association? Eur J Endocrinol 165:107-114
5. Pantos C, Mourouzis I, Galanopoulos G, Gavra M, Perimenis P, Spanou D, Cokkinos DV (2010) Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res 42:718-724
6. Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM (2008) Short term triiodo-l-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol 44:180-187
7. Chen YF, Pottala JV, Weltman NY, Ge X, Savinova OV, Gerdes AM (2012) Regulation of gene expression with thyroid hormone in rats with myocardial infarction. PLoS One 7:e40161
8. Forini F, Lionetti V, Ardehali H, Pucci A, Cecchetti F, Ghanefar M, Nicolini G, Ichikawa Y, Nannipieri M, Recchia FA, Iervasi G (2011) Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats. J Cell Mol Med 15:514-524
9. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM (2009) Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail 2:243-252
10. Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Kokkinos AD, Panagiotou M, Cokkinos DV (2007) Thyroid hormone attenuates cardiac remodelling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg 32:333-339
11. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV (2008) Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol 103:308-318
12. Pantos C, Mourouzis I, Tsagoulis N, Markakis K, Galanopoulos G, Roukounakis N, Perimenis P, Liappas A, Cokkinos DV (2009) Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J Physiol Pharmacol 60:49-56
13. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D (2008) Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications. Pharmacol Ther 118:277-294
14. Pantos C, Xinaris C, Mourouzis I, Perimenis P, Politi E, Spanou D, Cokkinos DV (2008) Thyroid hormone receptor alpha1: a switch to cardiac cell "metamorphosis"? J Physiol Pharmacol 59:253-269
15. Kinugawa K, Jeong MY, Bristow MR, Long CS (2005) Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol 19:1618-1628
16. Belakavadi M, Saunders J, Weisleder N, Raghava PS, Fondell JD (2010) Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-alpha1 and involves targeted covalent histone modifications. Endocrinology 151:2946-2956
17. Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Roukounakis N, Kokkinos AD, Cokkinos DV, Pantos C (2011) Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings. Mol Cell Biochem 363:235-243
18. Pantos C, Mourouzis I, Malliopoulou V, Paizis I, Tzeis S, Moraitis P, Sfakianoudis K, Varonos DD, Cokkinos DV (2005) Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor alpha1. Thyroid 15:16-23
19. Van Beeren HC, Jong WM, Kaptein E, Visser TJ, Bakker O, Wiersinga WM (2003) Dronerarone acts as a selective inhibitor of 3,5,3′- triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology 144:552-558
20. van Beeren HC, Kwakkel J, Ackermans MT, Wiersinga WM, Fliers E, Boelen A (2012) Action of specific thyroid hormone receptor alpha(1) and beta(1) antagonists in the central and peripheral regulation of thyroid hormone metabolism in the rat. Thyroid 22:1275-1282
21. Kalofoutis C, Mourouzis I, Galanopoulos G, Dimopoulos A, Perimenis P, Spanou D, Cokkinos DV, Singh J, Pantos C (2010) Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. Mol Cell Biochem 345:161-169
22. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn GW 2nd (1998) Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95:10140-10145
23. van Empel VP, De Windt LJ (2004) Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 63:487-499
24. Suarez J, Scott BT, Suarez-Ramirez JA, Chavira CV, Dillmann WH (2010) Thyroid hormone inhibits ERK phosphorylation in pressure overload-induced hypertrophied mouse hearts through a receptor-mediated mechanism. Am J Physiol Cell Physiol 299:C1524-C1529
25. Pantos C, Mourouzis I, Cokkinos DV (2011) New insights into the role of thyroid hormone in cardiac remodelling: time to reconsider? Heart Fail Rev 16:79-96
26. Pantos C, Mourouzis I, Cokkinos DV (2012) Thyroid hormone and cardiac repair/regeneration: from Prometheus myth to reality? Can J Physiol Pharmacol 90:977-987
27. Pantos C, Mourouzis I, Saranteas T, Brozou V, Galanopoulos G, Kostopanagiotou G, Cokkinos DV (2011) Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRalpha1 receptor. Mol Cell Biochem 353:235-241
28. Pantos C, Malliopoulou V, Varonos DD, Cokkinos DV (2004) Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol 99:101-120
29. Pantos C, Mourouzis I, Cokkinos DV (2010) Thyroid hormone as a therapeutic option for treating ischaemic heart disease: from early reperfusion to late remodelling. Vascul Pharmacol 52:157-165
30. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, Kass DA, Wang Y (2001) The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA 98:12283-12288
31. Vahebi S, Ota A, Li M, Warren CM, de Tombe PP, Wang Y, Solaro RJ (2007) p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res 100:408-415
32. Aikawa R, Nagai T, Kudoh S, Zou Y, Tanaka M, Tamura M, Akazawa H, Takano H, Nagai R, Komuro I (2002) Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension 39:233-238
33. Auger-Messier M, Accornero F, Goonasekera SA, Bueno OF, Lorenz JN, van Berlo JH, Willette RN, Molkentin JD (2012) Unrestrained p38 MAPK activation in Dusp1/4 double null mice induces cardiomyopathy. Circ Res 112(1):48-56
34. 2+ handling and contraction in cardiomyocytes from mice with a dominant negative thyroid hormone receptor alpha1. J Mol Cell Cardiol 38:655-663
35. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D (2012) Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 110:607-613
36. Pantos C, Mourouzis I (2011) Comment: worsening heart failure in the setting of dronedarone initiation. Ann Pharmacother 45:689